시장보고서
상품코드
1338972

소아 경련 치료제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 치료제 유형별, 치료제 유형별, 조제 및 투여 경로별, 유통 경로별, 지역별(2023-2032년)

Infantile Spasm Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class (Anticonvulsants, Corticosteroids, Others); By Drug Type; By Dosage, By Route of Administration; By Distribution Channel; and Region 2023 - 2032

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 소아 경련 치료제 시장 규모는 2032년까지 1억 8,185만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

시장은 제네릭 의약품을 포함한 획기적인 의약품 개발을 목격하고 있습니다. 예를 들어, MSN Labs는 인도 최초의 비가바트린 제네릭 의약품(비가넥스트)을 출시했으며, 이는 분말 형태로 투여됩니다. 최근 기술 발전은 특히 소아 경련 치료제의 사전 치료제와 예방 치료제에서 두드러지게 나타나고 있으며, 예를 들어 비침습적 자동 발작 감지 장치의 개발로 발작을 조기에 발견할 수 있는 비침습적 자동 발작 감지 장치가 개발되어 이 장애를 치료할 수 있는 더 나은 솔루션을 제공합니다. 원격 상담의 존재로 인해 소아 경련 치료제 시장은 감금 시대에 널리 사용되었기 때문에 급증했습니다. 이 엄청난 수요는 쉽고 편안한 검진, 세계 상담 등의 장점으로 인해 큰 수요를 보였습니다.

세계적으로 매년 12월 첫째 주에 열리는 '소아 경련 치료제 인식 주간'과 같은 인식 개선 캠페인이 존재하고 증가하고 있는 것은 시장에 긍정적인 영향을 미치는 데 기여하고 있습니다. 또한, 연구개발에 대한 투자가 집중되어 신약 개발이 증가함에 따라 신규 및 적합성 높은 의약품에 대한 수요가 증가하고 있습니다. 세계은행 자료에 따르면 세계 GDP의 2.63%가 시중에서 구할 수 있는 치료제를 대체할 수 있는 더 나은 치료제의 연구개발에 투자되고 있습니다.

소아 경련치료제 시장 보고서 하이라이트

항경련제가 가장 큰 매출 점유율을 차지합니다. 이는 높은 효과와 치료 중 환자의 내약성이 용이하기 때문입니다.

부신피질자극호르몬 부문은 안전성과 효과로 인해 임상의와 처방자가 소아 경련 치료제로 선호하고 있어 가장 큰 매출 점유율을 차지하고 있습니다.

소아 환자에게 투여하기 쉽고, 환자의 순응도가 높으며, 빠른 효과 발현 등의 장점으로 인해 액상 부문이 가장 큰 시장 점유율을 차지하고 있습니다.

소아 경련 치료제는 의사의 입회하에 복용해야 하고, 병원 약국은 다른 유통 형태에 비해 편의성이 높기 때문에 병원 부문이 가장 큰 시장 점유율을 차지하고 있습니다.

북미가 시장을 독점하고 있는 이유는 기술이 일찍부터 받아들여지고, 의료 인프라가 더 잘 갖추어져 있으며, 제품 혁신이 지속적으로 추진되고 있기 때문입니다.

시장의 주요 업체로는 Lundbeck, Mallinckrodt Pharmaceuticals, Market Catalyst Pharmaceuticals, GW Pharmaceuticals, Retrophin, Valerion Therapeutics, Orphelia Pharma, Insys Therapeutics, Anavex Life Sciences 등이 있다, Orphelia Pharma, Insys Therapeutics, Anavex Life Sciences 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 소아 경련 치료제 시장에 관한 인사이트

  • 소아 경련 치료제 - 업계 현황
  • 소아 경련 치료제 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTLE 분석
  • 소아 경련 치료제 업계 동향
  • COVID-19의 영향 분석

제5장 세계의 소아 경련 치료제 시장, 치료제 클래스별

  • 주요 조사 결과
  • 서론
  • 항경련제
  • 코르티코스테로이드
  • 기타

제6장 세계의 소아 경련 치료제 시장, 치료제 유형별

  • 주요 조사 결과
  • 서론
  • 비가바트린
  • 부신피질 자극 호르몬
  • 기타(단계Ⅲ)

제7장 세계의 소아 경련 치료제 시장, 조제별

  • 주요 조사 결과
  • 서론
  • 고체
  • 액체

제8장 세계의 소아 경련 치료제 시장, 투여 경로별

  • 주요 조사 결과
  • 서론
  • 경구
  • 비경구
  • 기타

제9장 세계의 소아 경련 치료제 시장, 유통 채널별

  • 주요 조사 결과
  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제10장 세계의 소아 경련 치료제 시장, 지역별

  • 주요 조사 결과
  • 서론
    • 소아 경련 치료제 시장 평가, 지역별, 2019-2032년
  • 소아 경련 치료제 시장 - 북미
    • 북미 : 소아 경련 치료제 시장, 치료제 클래스별, 2019-2032년
    • 북미 : 소아 경련 치료제 시장, 투여 경로별, 2019-2032년
    • 북미 : 소아 경련 치료제 시장, 치료제 유형별, 2019-2032년
    • 북미 : 소아 경련 치료제 시장, 조제별, 2019-2032년
    • 북미 : 소아 경련 치료제 시장, 유통 채널별, 2019-2032년
    • 소아 경련 치료제 시장 - 미국
    • 소아 경련 치료제 시장 - 캐나다
  • 소아 경련 치료제 시장 - 유럽
    • 유럽 : 소아 경련 치료제 시장, 치료제 클래스별, 2019-2032년
    • 유럽 : 소아 경련 치료제 시장, 투여 경로별, 2019-2032년
    • 유럽 : 소아 경련 치료제 시장, 치료제 유형별, 2019-2032년
    • 유럽 : 소아 경련 치료제 시장, 조제별, 2019-2032년
    • 유럽 : 소아 경련 치료제 시장, 유통 채널별, 2019-2032년
    • 소아 경련 치료제 시장 - 영국
    • 소아 경련 치료제 시장 - 프랑스
    • 소아 경련 치료제 시장 - 독일
    • 소아 경련 치료제 시장 - 이탈리아
    • 소아 경련 치료제 시장 - 스페인
    • 소아 경련 치료제 시장 - 네덜란드
    • 소아 경련 치료제 시장 - 러시아
  • 소아 경련 치료제 시장 - 아시아태평양
    • 아시아태평양 : 소아 경련 치료제 시장, 치료제 클래스별, 2019-2032년
    • 아시아태평양 : 소아 경련 치료제 시장, 투여 경로별, 2019-2032년
    • 아시아태평양 : 소아 경련 치료제 시장, 치료제 유형별, 2019-2032년
    • 아시아태평양 : 소아 경련 치료제 시장, 조제별, 2019-2032년
    • 아시아태평양 : 소아 경련 치료제 시장, 유통 채널별, 2019-2032년
    • 소아 경련 치료제 시장 - 중국
    • 소아 경련 치료제 시장 - 인도
    • 소아 경련 치료제 시장 - 일본
    • 소아 경련 치료제 시장 - 말레이시아
    • 소아 경련 치료제 시장 - 인도네시아
    • 소아 경련 치료제 시장 - 한국
  • 소아 경련 치료제 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 소아 경련 치료제 시장, 치료제 클래스별, 2019-2032년
    • 중동 및 아프리카 : 소아 경련 치료제 시장, 투여 경로별, 2019-2032년
    • 중동 및 아프리카 : 소아 경련 치료제 시장, 치료제 유형별, 2019-2032년
    • 중동 및 아프리카 : 소아 경련 치료제 시장, 조제별, 2019-2032년
    • 중동 및 아프리카 : 소아 경련 치료제 시장, 유통 채널별, 2019-2032년
    • 소아 경련 치료제 시장 - 사우디아라비아
    • 소아 경련 치료제 시장 - 아랍에미리트(UAE)
    • 소아 경련 치료제 시장 - 이스라엘
    • 소아 경련 치료제 시장 - 남아프리카
  • 소아 경련 치료제 시장 - 라틴아메리카
    • 라틴아메리카 : 소아 경련 치료제 시장, 치료제 클래스별, 2019-2032년
    • 라틴아메리카 : 소아 경련 치료제 시장, 투여 경로별, 2019-2032년
    • 라틴아메리카 : 소아 경련 치료제 시장, 치료제 유형별, 2019-2032년
    • 라틴아메리카 : 소아 경련 치료제 시장, 조제별, 2019-2032년
    • 라틴아메리카 : 소아 경련 치료제 시장, 유통 채널별, 2019-2032년
    • 소아 경련 치료제 시장 - 멕시코
    • 소아 경련 치료제 시장 - 브라질
    • 소아 경련 치료제 시장 - 아르헨티나

제11장 경쟁 구도

  • 확장 및 인수 분석
    • 확장
    • 인수
  • 제휴/협업/합의/공개

제12장 기업 개요

  • Lundbeck
  • Mallinckrodt Pharmaceuticals
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • Retrophin
  • Valerion Therapeutics
  • Orphelia Pharma
  • Insys Therapeutics
  • Anavex Life Sciences Corp
LSH 23.09.15

The infantile spasm therapeutics market size is expected to reach USD 181.85 million by 2032, according to a new study by Polaris Market Research. The report "Infantile Spasm Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class (Anticonvulsants, Corticosteroids, Others); By Drug Type; By Dosage, By Route of Administration; By Distribution Channel; and Region 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market has witnessed some revolutionary drug developments including generic drugs, for e.g., MSN Labs launched India's first generic Vigabatrin (Viganext) that is to be administered as a powder. The recent technological advancements particularly in advance treatment and preventive treatment of Infantile Spasm Therapeutics, like development of non-invasive automated seizure detection device that help in early detection of seizure to provide better solutions for to treat the disorder. Due to presence of telemedicine and teleconsultation, during the times of COVID-19, Infantile Spasm Therapeutics market has seen a jump as it was widely used during the times of lockdown. This huge demand was seen due to the advantages of easy and comfortable check-up, consultation from across the globe amongst others.

The presence and increase of awareness campaigns like that of Infantile Spasm Therapeutics Awareness Week every first week of December across the globe contribute to positively impacting the market. Also, the growing demand for novel and compliant drugs is made possible by an increasing concentration on investments associated to research and development, which leads to an increase in new drug development. According to World Bank data, 2.63% of global GDP is invested in research and development of better alternatives to the drugs available in the market.

Infantile Spasm Therapeutics Market Report Highlights

The anticonvulsants segment accounted for the largest revenue share. This is due to its higher efficacy and ease of tolerance in patients undergoing treatment

Adrenocorticotropic hormone segment accounted to hold largest revenue share as it is preferred by the clinicians and prescribers to treat Infantile Spasm Therapeutics owing to its safety and efficacy making it the drug of choice

Liquid segment accounted for largest market share due to its advantages like ease of administration in infantile patients, high patient compliance, and rapid onset of action

Hospital Pharmacy segment account for a largest market share owing to the reason that Infantile Spasm Therapeutics requires treatment in presence of a medical practitioner and, hospital pharmacies provide convenience as compared to other modes of distribution

North America dominated the market as there is more early acceptance of techniques, better and more developed healthcare infrastructure and constant drive for product innovation.

The major players in the market include Lundbeck, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals, Retrophin, Valerion Therapeutics, Orphelia Pharma, Insys Therapeutics, & Anavex Life Sciences.

Polaris Market Research has segmented the Infantile Spasm Therapeutics market report based on therapeutic class, dosage, route of administration, distribution channel, drug type, and region:

Infantile Spasm Therapeutics Market, Therapeutic Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasm Therapeutics Market, Drug Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Infantile Spasm Therapeutics Market, Dosage Outlook (Revenue - USD Million, 2019 - 2032)

  • Solid
  • Liquid

Infantile Spasm Therapeutics Market, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parenteral
  • Others

Infantile Spasm Therapeutics Market, Distribution Channel Outlook (Revenue - USD Million, 2019 -2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Infantile Spasm Therapeutics Market, Region Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Infantile Spasm Therapeutics Market Insights

  • 4.1. Infantile Spasm Therapeutics - Industry Snapshot
  • 4.2. Infantile Spasm Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising incidence of infantile spasms in newborns
      • 4.2.1.2. Increasing government supports
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Infantile Spasm Therapeutics Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Infantile Spasm Therapeutics Market, by Therapeutic Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
  • 5.3. Anticonvulsants
    • 5.3.1. Global Infantile Spasm Therapeutics Market, by Anticonvulsants, by Region, 2019-2032 (USD Million)
  • 5.4. Corticosteroids
    • 5.4.1. Global Infantile Spasm Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Infantile Spasm Therapeutics Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Infantile Spasm Therapeutics Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
  • 6.3. Vigabatrin
    • 6.3.1. Global Infantile Spasm Therapeutics Market, by Vigabatrin, by Region, 2019-2032 (USD Million)
  • 6.4. Adrenocorticotropic Hormone
    • 6.4.1. Global Infantile Spasm Therapeutics Market, by Adrenocorticotropic Hormone, by Region, 2019-2032 (USD Million)
  • 6.5. Others (Phase III)
    • 6.5.1. Global Infantile Spasm Therapeutics Market, by Others (Phase III), by Region, 2019-2032 (USD Million)

7. Global Infantile Spasm Therapeutics Market, by Dosage

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
  • 7.3. Solid
    • 7.3.1. Global Infantile Spasm Therapeutics Market, by Solid, by Region, 2019-2032 (USD Million)
  • 7.4. Liquid
    • 7.4.1. Global Infantile Spasm Therapeutics Market, by Liquid, by Region, 2019-2032 (USD Million)

8. Global Infantile Spasm Therapeutics Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.3. Oral
    • 8.3.1. Global Infantile Spasm Therapeutics Market, by Oral, by Region, 2019-2032 (USD Million)
  • 8.4. Parenteral
    • 8.4.1. Global Infantile Spasm Therapeutics Market, by Parenteral, by Region, 2019-2032 (USD Million)
  • 8.5. Others
    • 8.5.1. Global Infantile Spasm Therapeutics Market, by Others, by Region, 2019-2032 (USD Million)

9. Global Infantile Spasm Therapeutics Market, by Distribution Channel

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.3. Hospital Pharmacy
    • 9.3.1. Global Infantile Spasm Therapeutics Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Million)
  • 9.4. Retail Pharmacy
    • 9.4.1. Global Infantile Spasm Therapeutics Market, by Retail Pharmacy, by Region, 2019-2032 (USD Million)
  • 9.5. Online Pharmacy
    • 9.5.1. Global Infantile Spasm Therapeutics Market, by Online Pharmacy, by Region, 2019-2032 (USD Million)

10. Global Infantile Spasm Therapeutics Market, by Geography

  • 10.1. Key findings
  • 10.2. Introduction
    • 10.2.1. Infantile Spasm Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
  • 10.3. Infantile Spasm Therapeutics Market - North America
    • 10.3.1. North America: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.3.2. North America: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.3.3. North America: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.3.4. North America: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.3.5. North America: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.3.6. Infantile Spasm Therapeutics Market - U.S.
      • 10.3.6.1. U.S.: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.3.6.2. U.S.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.3.6.3. U.S.: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.3.6.4. U.S.: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.3.6.5. U.S.: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.3.7. Infantile Spasm Therapeutics Market - Canada
      • 10.3.7.1. Canada: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.3.7.2. Canada.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.3.7.3. Canada: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.3.7.4. Canada: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.3.7.5. Canada: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.4. Infantile Spasm Therapeutics Market - Europe
    • 10.4.1. Europe: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.4.2. Europe.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.4.3. Europe: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.4.4. Europe: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.4.5. Europe: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.6. Infantile Spasm Therapeutics Market - UK
      • 10.4.6.1. UK: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.6.2. UK.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.6.3. UK: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.6.4. UK: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.6.5. UK: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.7. Infantile Spasm Therapeutics Market - France
      • 10.4.7.1. France: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.7.2. France.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.7.3. France: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.7.4. France: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.7.5. France: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.8. Infantile Spasm Therapeutics Market - Germany
      • 10.4.8.1. Germany: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.8.2. Germany.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.8.3. Germany: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.8.4. Germany: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.8.5. Germany: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.9. Infantile Spasm Therapeutics Market - Italy
      • 10.4.9.1. Italy: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.9.2. Italy.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.9.3. Italy: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.9.4. Italy: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.9.5. Italy: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.10. Infantile Spasm Therapeutics Market - Spain
      • 10.4.10.1. Spain: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.10.2. Spain.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.10.3. Spain: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.10.4. Spain: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.10.5. Spain: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.11. Infantile Spasm Therapeutics Market - Netherlands
      • 10.4.11.1. Netherlands: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.11.2. Netherlands.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.11.3. Netherlands: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.11.4. Netherlands: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.11.5. Netherlands: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.12. Infantile Spasm Therapeutics Market - Russia
      • 10.4.12.1. Russia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.12.2. Russia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.12.3. Russia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.12.4. Russia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.12.5. Russia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.5. Infantile Spasm Therapeutics Market - Asia Pacific
    • 10.5.1. Asia Pacific: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.5.2. Asia Pacific.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.5.3. Asia Pacific: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.5.4. Asia Pacific: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.5.5. Asia Pacific: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.6. Infantile Spasm Therapeutics Market - China
      • 10.5.6.1. China: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.6.2. China.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.6.3. China: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.6.4. China: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.6.5. China: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.7. Infantile Spasm Therapeutics Market - India
      • 10.5.7.1. India: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.7.2. India.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.7.3. India: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.7.4. India: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.7.5. India: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.8. Infantile Spasm Therapeutics Market - Japan
      • 10.5.8.1. Japan: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.8.2. Japan.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.8.3. Japan: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.8.4. Japan: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.8.5. Japan: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.9. Infantile Spasm Therapeutics Market - Malaysia
      • 10.5.9.1. Malaysia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.9.2. Malaysia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.9.3. Malaysia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.9.4. Malaysia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.9.5. Malaysia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.10. Infantile Spasm Therapeutics Market - Indonesia
      • 10.5.10.1. Indonesia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.10.2. Indonesia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.10.3. Indonesia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.10.4. Indonesia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.10.5. Indonesia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.11. Infantile Spasm Therapeutics Market - South Korea
      • 10.5.11.1. South Korea: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.11.2. South Korea.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.11.3. South Korea: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.11.4. South Korea: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.11.5. South Korea: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.6. Infantile Spasm Therapeutics Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.6.2. Middle East & Africa: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.6.3. Middle East & Africa: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.6.4. Middle East & Africa: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.6.5. Middle East & Africa: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.6. Infantile Spasm Therapeutics Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.6.2. Saudi Arabia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.6.3. Saudi Arabia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.6.4. Saudi Arabia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.6.5. Saudi Arabia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.7. Infantile Spasm Therapeutics Market - UAE
      • 10.6.7.1. UAE: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.7.2. UAE.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.7.3. UAE: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.7.4. UAE: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.7.5. UAE: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.8. Infantile Spasm Therapeutics Market - Israel
      • 10.6.8.1. Israel: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.8.2. Israel.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.8.3. Israel: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.8.4. Israel: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.8.5. Israel: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.9. Infantile Spasm Therapeutics Market - South Africa
      • 10.6.9.1. South Africa: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.9.2. South Africa.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.9.3. South Africa: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.9.4. South Africa: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.9.5. South Africa: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.7. Infantile Spasm Therapeutics Market - Latin America
    • 10.7.1. Latin America: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.7.2. Latin America.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.7.3. Latin America: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.7.4. Latin America: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.7.5. Latin America: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.6. Infantile Spasm Therapeutics Market - Mexico
      • 10.7.6.1. Mexico: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.6.2. Mexico.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.6.3. Mexico: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.6.4. Mexico: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.6.5. Mexico: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.7. Infantile Spasm Therapeutics Market - Brazil
      • 10.7.7.1. Brazil: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.7.2. Brazil.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.7.3. Brazil: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.7.4. Brazil: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.7.5. Brazil: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.8. Infantile Spasm Therapeutics Market - Argentina
      • 10.7.8.1. Argentina: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.8.2. Argentina.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.8.3. Argentina: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.8.4. Argentina: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.8.5. Argentina: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. Lundbeck
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Mallinckrodt Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. Catalyst Pharmaceuticals
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. GW Pharmaceuticals
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Retrophin
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Valerion Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. Orphelia Pharma
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Insys Therapeutics
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. Anavex Life Sciences Corp
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제